Literature DB >> 10469327

Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.

J A McGrath1, G H Ashton, J E Mellerio, J C Salas-Alanis, O Swensson, J R McMillan, R A Eady.   

Abstract

Non-sense mutations on both alleles of either the type VII collagen gene (COL7A1) or the genes encoding laminin 5 (LAMA3, LAMB3, or LAMC2) usually result in clinically severe forms of recessive dystrophic or junctional epidermolysis bullosa, respectively. In this study we assessed two unrelated families whose mutations in genomic DNA predicted severe recessive dystrophic epidermolysis bullosa or junctional epidermolysis bullosa phenotypes but in whom the manifestations were milder than expected. The recessive dystrophic epidermolysis bullosa patients had a homozygous single base-pair frameshift mutation in exon 19 of COL7A1 (2470insG). Clinically, there was generalized blistering but only mild scarring. Skin biopsy revealed positive type VII collagen immunoreactivity and recognizable anchoring fibrils. The junctional epidermolysis bullosa patients were compound heterozygotes for a frameshift/non-sense combination of mutations in exons 3 and 17 of LAMB3 (29insC/Q834X). These patients did not have the lethal form of junctional epidermolysis bullosa but, as adults, displayed the milder generalized atrophic benign epidermolysis bullosa variant. There was undetectable laminin 5 staining at the dermal-epidermal junction using an antibody to the beta3 chain, but faintly positive alpha3 and gamma2 chain labeling, and there was variable hypoplasia of hemidesmosomes. To explain the milder recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa phenotypes in these families, reverse transcription-polymerase chain reaction, using RNA extracted from frozen skin, was able to provide evidence for some rescue of mutant mRNA transcripts with restoration of the open- reading frame. In the recessive dystrophic epidermolysis bullosa patients, transcripts containing in-frame skipping of exon 19 of COL7A1 in the cDNA were detected, and in the junctional epidermolysis bullosa patients transcripts with in-frame skipping of exon 17 of LAMB3 were identified. The truncated proteins encoded by these transcripts are expected to lack certain critical domains involved in cell-matrix attachment, but may still be able to contribute to adhesion thereby moderating the severity of the skin blistering. This study shows the limitations in predicting phenotype in epidermolysis bullosa solely based on mutation analysis of genomic DNA and emphasizes the importance of immunohistochemistry, electron microscopy, and mRNA assessment as parallel investigations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469327     DOI: 10.1046/j.1523-1747.1999.00709.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

Review 1.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

2.  Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes.

Authors:  Roslyn Varki; Sara Sadowski; Jouni Uitto; Ellen Pfendner
Journal:  J Med Genet       Date:  2006-09-13       Impact factor: 6.318

3.  Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease.

Authors:  Christiane Mühle; Qiu-Jie Jiang; Alexandra Charlesworth; Leena Bruckner-Tuderman; Guerrino Meneguzzi; Holm Schneider
Journal:  Hum Genet       Date:  2004-11-05       Impact factor: 4.132

4.  Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.

Authors:  Olivier Bornert; Tobias Kühl; Jeroen Bremer; Peter C van den Akker; Anna Mg Pasmooij; Alexander Nyström
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

Review 5.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 6.  Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.

Authors:  Cristina Has; Andrew South; Jouni Uitto
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

7.  A COL7A1 Variant in a Litter of Neonatal Basset Hounds with Dystrophic Epidermolysis Bullosa.

Authors:  Teresa Maria Garcia; Sarah Kiener; Vidhya Jagannathan; Duncan S Russell; Tosso Leeb
Journal:  Genes (Basel)       Date:  2020-12-04       Impact factor: 4.096

8.  Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1.

Authors:  Kristin A Ham; May Thandar Aung-Htut; Sue Fletcher; Steve D Wilton
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

9.  Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.

Authors:  Michael Ablinger; Thomas Lettner; Nicole Friedl; Hannah Potocki; Theresa Palmetzhofer; Ulrich Koller; Julia Illmer; Bernadette Liemberger; Stefan Hainzl; Alfred Klausegger; Manuela Reisenberger; Jo Lambert; Mireille Van Gele; Eline Desmet; Els Van Maelsaeke; Monika Wimmer; Roland Zauner; Johann W Bauer; Verena Wally
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

Review 10.  Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa.

Authors:  Tobias Welponer; Christine Prodinger; Josefina Pinon-Hofbauer; Arno Hintersteininger; Hannelore Breitenbach-Koller; Johann W Bauer; Martin Laimer
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.